{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:59:41Z","timestamp":1781647181481,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA044878"],"award-info":[{"award-number":["R01DA044878"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24DA057873"],"award-info":[{"award-number":["K24DA057873"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Buprenorphine is an effective medication for opioid use disorder (OUD) treatment; however, stigma surrounding substance use may deter individuals from seeking treatment and contribute to lower engagement once treatment is initiated. This study examined relationships between substance use stigma and buprenorphine treatment engagement among syringe service program (SSP) participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional secondary analysis used data from a randomized control trial of buprenorphine treatment initiation at three SSPs. Participants met DSM-5 criteria for OUD and expressed interest in buprenorphine. Participants completed the Ahern substance use stigma scale at baseline. The primary outcome was buprenorphine engagement, defined as having an active prescription 30 days post-enrollment. Multivariable logistic regression examined associations between participants\u2019 perceived stigma and buprenorphine engagement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-seven participants with a mean age of 42 years reported high levels of substance use stigma across multiple domains (discrimination, alienation, perceived devaluation); however, there were no significant differences in stigma scores between those who were and were not engaged in buprenorphine at 30 days. Participants who reported being denied medical care previously due to their substance use were significantly more likely to engage in buprenorphine (adjusted Odds Ratio\u2009=\u20092.64, 95% CI\u2009=\u20091.04\u20136.66).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Stigma scores did not predict buprenorphine engagement, but unexpectedly, participants who had experienced discrimination in medical care were more likely to engage. While stigma was not associated with buprenorphine uptake, most participants reported high levels of stigma, highlighting the need for patient-centered models of care that mitigate stigma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-026-00665-3","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:36:21Z","timestamp":1775788581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does perceived stigma impact opioid use disorder treatment uptake? A cross-sectional secondary analysis of buprenorphine engagement among syringe service program participants"],"prefix":"10.1186","volume":"21","author":[{"given":"Bailey","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Riback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Gatica","family":"Portillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Maricic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"665_CR1","doi-asserted-by":"publisher","first-page":"103786","DOI":"10.1016\/j.drugpo.2022.103786","volume":"110","author":"N Krawczyk","year":"2022","unstructured":"Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerd\u00e1 M. Has the treatment gap for opioid use disorder narrowed in the U.S.? A yearly assessment from 2010 to 2019. Int J Drug Policy. 2022;110:103786. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103786. Epub 2022 Aug 4. PMID: 35934583; PMCID: PMC10976290.","journal-title":"Int J Drug Policy"},{"key":"665_CR2","doi-asserted-by":"crossref","unstructured":"Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine vs placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.","DOI":"10.1002\/14651858.CD002207.pub4"},{"issue":"2","key":"665_CR3","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"665_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10550887.2012.694598","volume":"31","author":"G Bart","year":"2012","unstructured":"Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207\u201325. https:\/\/doi.org\/10.1080\/10550887.2012.694598.","journal-title":"J Addict Dis"},{"issue":"1","key":"665_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1802741","volume":"379","author":"SE Wakeman","year":"2018","unstructured":"Wakeman SE, Barnett ML. Primary care and the opioid-overdose crisis \u2014 buprenorphine myths and realities. N Engl J Med. 2018;379(1):1\u20134.","journal-title":"N Engl J Med"},{"key":"665_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev.soc.27.1.363","volume":"27","author":"BG Link","year":"2001","unstructured":"Link BG, Phelan JC. Conceptualizing stigma. Annu Rev Sociol. 2001;27:363\u201385.","journal-title":"Annu Rev Sociol"},{"issue":"2\u20133","key":"665_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.10.014","volume":"88","author":"J Ahern","year":"2007","unstructured":"Ahern J, Stuber J, Galea S. Stigma, discrimination and the health of illicit drug users. Drug Alcohol Depend. 2007;88(2\u20133):188\u201396.","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"665_CR8","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1037\/amp0000744","volume":"75","author":"VA Earnshaw","year":"2020","unstructured":"Earnshaw VA. Stigma and substance use disorders: a clinical, research, and advocacy agenda. Am Psychol. 2020;75(9):1300\u201311.","journal-title":"Am Psychol"},{"issue":"11","key":"665_CR9","doi-asserted-by":"publisher","first-page":"e1002969","DOI":"10.1371\/journal.pmed.1002969","volume":"16","author":"AC Tsai","year":"2019","unstructured":"Tsai AC, Kiang MV, Barnett ML, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019;16(11):e1002969.","journal-title":"PLoS Med"},{"key":"665_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","volume":"131","author":"LC van Boekel","year":"2013","unstructured":"van Boekel LC, Brouwers EP, van Weeghel J, Garretsen HF. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131:23\u201335.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"665_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13722-023-00386-x","volume":"18","author":"A Jakubowski","year":"2023","unstructured":"Jakubowski A, Singh-Tan S, Torres-Lockhart K, et al. Hospital-based clinicians lack knowledge and comfort in initiating medications for opioid use disorder: opportunities for training innovation. Addict Sci Clin Pract. 2023;18(1):31.","journal-title":"Addict Sci Clin Pract"},{"issue":"3","key":"665_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.drugpo.2009.10.010","volume":"21","author":"JF Kelly","year":"2010","unstructured":"Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. Int J Drug Policy. 2010;21(3):202\u20137.","journal-title":"Int J Drug Policy"},{"key":"665_CR13","first-page":"327","volume":"17","author":"JO Merrill","year":"2002","unstructured":"Merrill JO, Rhodes LA, Deyo RA, Marlatt GA, Bradley KA. Mutual mistrust in the medical care of drug users: the keys to the narc cabinet. J Gen Intern Med. 2002;17:327\u201333.","journal-title":"J Gen Intern Med"},{"key":"665_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12954-025-01166-3","volume":"22","author":"Z Papalamprakopoulou","year":"2025","unstructured":"Papalamprakopoulou Z, Ntagianta E, Triantafyllou V, et al. Breaking the vicious cycle of delayed healthcare seeking for people who use drugs. Harm Reduct J. 2025;22:27.","journal-title":"Harm Reduct J"},{"key":"665_CR15","doi-asserted-by":"publisher","first-page":"108589","DOI":"10.1016\/j.drugalcdep.2021.108589","volume":"221","author":"C Fong","year":"2021","unstructured":"Fong C, Mateu-Gelabert P, Ciervo C, et al. Medical provider stigma experienced by people who use drugs (MPS-PWUD): scale development and validation. Drug Alcohol Depend. 2021;221:108589.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"665_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12954-019-0285-7","volume":"16","author":"S Chan Carusone","year":"2019","unstructured":"Chan Carusone S, Guta A, Robinson S, et al. Maybe if I stop the drugs, then maybe they\u2019d care?\u2014hospital care experiences of people who use drugs. Harm Reduct J. 2019;16(1):16.","journal-title":"Harm Reduct J"},{"key":"665_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"198","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"665_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","volume":"17","author":"B Muncan","year":"2020","unstructured":"Muncan B, Walters SM, Ezell J, Ompad DC. They look at us like junkies: influence of stigma on healthcare engagement among people who inject drugs in NYC. Harm Reduct J. 2020;17(1):53.","journal-title":"Harm Reduct J"},{"key":"665_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.drugalcdep.2014.09.778","volume":"144","author":"AV Rivera","year":"2014","unstructured":"Rivera AV, DeCuir J, Crawford ND, Amesty S, Lewis CF. Internalized stigma and sterile syringe use among people who inject drugs in NYC, 2010\u20132012. Drug Alcohol Depend. 2014;144:259\u201364.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"665_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.apnu.2015.07.008","volume":"29","author":"G Can","year":"2015","unstructured":"Can G, Tanr\u0131verdi D. Social functioning and internalized stigma in individuals diagnosed with substance use disorder. Arch Psychiatr Nurs. 2015;29(6):441\u20136.","journal-title":"Arch Psychiatr Nurs"},{"issue":"1","key":"665_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/clipsy.9.1.35","volume":"9","author":"PW Corrigan","year":"2002","unstructured":"Corrigan PW, Watson AC. The paradox of self-stigma and mental illness. Clin Psychol Sci Pract. 2002;9(1):35\u201353.","journal-title":"Clin Psychol Sci Pract"},{"issue":"3","key":"665_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/15332640.2017.1357158","volume":"18","author":"S Sarker","year":"2019","unstructured":"Sarker S, Saha I, Ghosh S, Haldar D, Ghosh A. Internalized stigma among patients with substance use disorders in India. J Ethn Subst Abuse. 2019;18(3):345\u201358.","journal-title":"J Ethn Subst Abuse"},{"issue":"5","key":"665_CR23","first-page":"361","volume":"11","author":"N Bozinoff","year":"2017","unstructured":"Bozinoff N, DeBeck K, Milloy MJ, et al. Correlates of stigma severity among persons seeking opioid detoxification. J Addict Med. 2017;11(5):361\u20136.","journal-title":"J Addict Med"},{"key":"665_CR24","doi-asserted-by":"publisher","first-page":"117822182211038","DOI":"10.1177\/11782218221103859","volume":"16","author":"J Dickson-Gomez","year":"2022","unstructured":"Dickson-Gomez J, McAuliffe T, Quinn K, Young A, Johnson J, Owczarzak J. You\u2019re not supposed to be on it forever: MOUD-related stigma among providers and people who use opioids. Subst Abuse Res Treat. 2022;16:11782218221103859.","journal-title":"Subst Abuse Res Treat"},{"issue":"9","key":"665_CR25","doi-asserted-by":"publisher","first-page":"628","DOI":"10.7326\/M18-1652","volume":"169","author":"SA Martin","year":"2018","unstructured":"Martin SA, Chiodo LM, Bosse JD, Wilson A. The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2018;169(9):628\u201335.","journal-title":"Ann Intern Med"},{"key":"665_CR26","doi-asserted-by":"publisher","first-page":"108627","DOI":"10.1016\/j.drugalcdep.2021.108627","volume":"221","author":"EM Stone","year":"2021","unstructured":"Stone EM, Kennedy-Hendricks A, Barry CL, Bachhuber MA, McGinty EE. The role of stigma in U.S. primary care physicians\u2019 treatment of opioid use disorder. Drug Alcohol Depend. 2021;221:108627.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"665_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13722-024-00436-y","volume":"19","author":"B Franz","year":"2024","unstructured":"Franz B, Dhanani LY, Hall OT, et al. Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals. Addict Sci Clin Pract. 2024;19(1):7.","journal-title":"Addict Sci Clin Pract"},{"key":"665_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12875-019-1047-z","volume":"20","author":"DL Louie","year":"2019","unstructured":"Louie DL, Assefa MT, McGovern MP. Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review. BMC Fam Pract. 2019;20:157.","journal-title":"BMC Fam Pract"},{"key":"665_CR29","doi-asserted-by":"publisher","first-page":"209633","DOI":"10.1016\/j.josat.2025.209633","volume":"171","author":"B Franz","year":"2025","unstructured":"Franz B, Dhanani LY, Bogart S, et al. Different forms of stigma and rural primary care professionals\u2019 willingness to prescribe buprenorphine. J Subst Use Addict Treat. 2025;171:209633.","journal-title":"J Subst Use Addict Treat"},{"issue":"5","key":"665_CR30","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11606-017-4289-2","volume":"33","author":"AP Goddu","year":"2018","unstructured":"Goddu AP, O\u2019Conor KJ, Lanzkron S, et al. Do words matter? Stigmatizing language and the transmission of bias in the medical record. J Gen Intern Med. 2018;33(5):685\u201391.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"665_CR31","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/08897077.2021.1901173","volume":"42","author":"T Frost","year":"2021","unstructured":"Frost T, Deutsch S, Brown S, et al. We\u2019ll be able to take care of ourselves - A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs. Subst Abus. 2021;42(4):983\u20139.","journal-title":"Subst Abus"},{"issue":"2","key":"665_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/08897077.2015.1011820","volume":"36","author":"AD Fox","year":"2015","unstructured":"Fox AD, Chamberlain A, Frost T, Cunningham CO. Harm reduction agencies as a potential site for buprenorphine treatment. Subst Abuse. 2015;36(2):155\u201360.","journal-title":"Subst Abuse"},{"issue":"1","key":"665_CR33","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/07853890.2023.2182908","volume":"55","author":"E Suarez Jr","year":"2023","unstructured":"Suarez E Jr, Bartholomew TS, Plesons M, et al. Adaptation of the Tele-Harm Reduction intervention to promote buprenorphine initiation and retention. Ann Med. 2023;55(1):733\u201343.","journal-title":"Ann Med"},{"key":"665_CR34","unstructured":"Jakubowski A, Luo SX, Velez C, et al. Low-threshold buprenorphine treatment in a syringe services program. J Addict Med. 2022 Jan-Feb;16(1):83\u20139."},{"issue":"2","key":"665_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","volume":"14","author":"A Jakubowski","year":"2020","unstructured":"Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med. 2020;14(2):95\u20138.","journal-title":"J Addict Med"},{"issue":"1","key":"665_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12954-022-00654-0","volume":"19","author":"A Jakubowski","year":"2022","unstructured":"Jakubowski A, Norton B, Hayes BT, Martinez-Hume A, Fox AD. Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation. Harm Reduct J. 2022;19(1):76.","journal-title":"Harm Reduct J"},{"issue":"1","key":"665_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jsat.2014.07.015","volume":"48","author":"AD Fox","year":"2014","unstructured":"Fox AD, Chamberlain A, Sohler NL, Frost T, Cunningham CO. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. J Subst Abuse Treat. 2014;48(1):112\u20136.","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"665_CR38","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1080\/10826084.2021.1908360","volume":"56","author":"BT Hayes","year":"2021","unstructured":"Hayes BT, Jakubowski A, Fitzsimmons C, Garcia B, Ramirez F, Fox AD. The Doctor Says You Cannot Have [Buprenorphine] Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine. Subst Use Misuse. 2021;56(8):1137\u201343.","journal-title":"Subst Use Misuse"},{"key":"665_CR39","doi-asserted-by":"publisher","first-page":"106674","DOI":"10.1016\/j.cct.2021.106674","volume":"114","author":"A Perez-Correa","year":"2022","unstructured":"Perez-Correa A, Abbas B, Riback L, et al. Onsite buprenorphine inductions at harm reduction agencies: design and rationale. Contemp Clin Trials. 2022;114:106674.","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"665_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12954-017-0149-y","volume":"14","author":"AD Fox","year":"2017","unstructured":"Fox AD, Sohler NL, Frost T, Lopez C, Cunningham CO. Development and evaluation of a community-based buprenorphine treatment intervention. Harm Reduct J. 2017;14(1):23.","journal-title":"Harm Reduct J"},{"key":"665_CR41","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Publishing; 2013.","edition":"5"},{"issue":"2","key":"665_CR42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) \u2013 A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377\u201381.","journal-title":"J Biomed Inf"},{"key":"665_CR43","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software partners. J Biomed Inf. 2019;95:103208.","journal-title":"J Biomed Inf"},{"issue":"8","key":"665_CR44","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamainternmed.2014.2556","volume":"174","author":"JM Liebschutz","year":"2014","unstructured":"Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine Treatment for Hospitalized, Opioid-Dependent Patients: A Randomized Clinical Trial. JAMA Intern Med. 2014;174(8):1369\u201376.","journal-title":"JAMA Intern Med"},{"issue":"16","key":"665_CR45","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1001\/jama.2015.3474","volume":"313","author":"G D\u2019Onofrio","year":"2015","unstructured":"D\u2019Onofrio G, O\u2019Connor PG, Pantalon MV, et al. Emergency Department\u2013Initiated Buprenorphine\/Naloxone Treatment for Opioid Dependence: A Randomized Clinical Trial. JAMA. 2015;313(16):1636\u201344.","journal-title":"JAMA"},{"issue":"2","key":"665_CR46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2307\/2955424","volume":"38","author":"BG Link","year":"1997","unstructured":"Link BG, Struening EL, Rahav M, Phelan JC, Nuttbrock L. On stigma and its consequences: evidence from a longitudinal study of men with dual diagnoses. J Health Soc Behav. 1997;38(2):177\u201390.","journal-title":"J Health Soc Behav"},{"issue":"1","key":"665_CR47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2307\/2137286","volume":"36","author":"IH Meyer","year":"1995","unstructured":"Meyer IH. Minority stress and mental health in gay men. J Health Soc Behav. 1995;36(1):38\u201356.","journal-title":"J Health Soc Behav"},{"issue":"1","key":"665_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.psychres.2003.08.008","volume":"121","author":"JB Ritsher","year":"2003","unstructured":"Ritsher JB, Otilingam PG, Grajales M. Internalized stigma of mental illness: psychometric properties of a new measure. Psychiatry Res. 2003;121(1):31\u201349.","journal-title":"Psychiatry Res"},{"key":"665_CR49","doi-asserted-by":"publisher","first-page":"108593","DOI":"10.1016\/j.jsat.2021.108593","volume":"132","author":"NM Brousseau","year":"2022","unstructured":"Brousseau NM, Farmer H, Karpyn A, Laurenceau JP, Kelly JF, Hill EC, Earnshaw VA. Qualitative characterizations of misinformed disclosure reactions to medications for opioid use disorders and their consequences. J Subst Abuse Treat. 2022;132:108593.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"665_CR50","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1353\/hpu.2014.0185","volume":"25","author":"L Ostrow","year":"2014","unstructured":"Ostrow L, Manderscheid R, Mojtabai R. Stigma and difficulty accessing medical care among adults with serious mental illness. J Health Care Poor Underserved. 2014;25(4):1953\u201362.","journal-title":"J Health Care Poor Underserved"},{"issue":"2","key":"665_CR51","first-page":"264","volume":"41","author":"AC Martinez-Hume","year":"2017","unstructured":"Martinez-Hume AC, Strike C, Guta A, et al. They treat you a different way: public insurance, stigma, and health care quality. Cult Med Psychiatry. 2017;41(2):264\u201384.","journal-title":"Cult Med Psychiatry"},{"key":"665_CR52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugalcdep.2016.02.019","volume":"162","author":"LR Smith","year":"2016","unstructured":"Smith LR, Earnshaw VA, Copenhaver MM, Cunningham CO. Substance use stigma: reliability and validity of a theory-based scale. Drug Alcohol Depend. 2016;162:34\u201343.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"665_CR53","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/ACM.0000000000005467","volume":"99","author":"E Magnan","year":"2024","unstructured":"Magnan E, Weyrich M, Miller M, Melnikow J, Moulin A, Servis M, Chadha P, Spivack S, Henry SG. Stigma Against Patients With Substance Use Disorders Among Health Care Professionals and Trainees and Stigma-Reducing Interventions: A Systematic Review. Acad Med. 2024;99(2):221\u201331.","journal-title":"Acad Med"},{"key":"665_CR54","doi-asserted-by":"publisher","first-page":"108486","DOI":"10.1016\/j.jsat.2021.108486","volume":"131","author":"J Bielenberg","year":"2021","unstructured":"Bielenberg J, Swisher G, Lembke A, Haug NA. A systematic review of stigma interventions for providers who treat patients with substance use disorders. J Subst Abuse Treat. 2021;131:108486.","journal-title":"J Subst Abuse Treat"},{"key":"665_CR55","doi-asserted-by":"crossref","unstructured":"Kazal HR, Walker-Elders A, Craig WY, Brokos Z, Anderson M, Silvia K, Hall K, Cote M, Cohen Konrad S, Thakarar K. The impact of interprofessional harm reduction trainings on clinician and student knowledge, attitude, and stigma. Subst Use Addctn J. 2025 Dec 17:29767342251391562.","DOI":"10.1177\/29767342251391562"},{"key":"665_CR56","doi-asserted-by":"publisher","first-page":"639826","DOI":"10.3389\/fpsyt.2021.639826","volume":"12","author":"HA Russell","year":"2021","unstructured":"Russell HA, Smith B, Sanders M, Loomis E. Attending a Biopsychosocially Focused Buprenorphine Training Improves Clinician Attitudes. Front Psychiatry. 2021;12:639826.","journal-title":"Front Psychiatry"},{"key":"665_CR57","doi-asserted-by":"publisher","first-page":"108872","DOI":"10.1016\/j.jsat.2022.108872","volume":"143","author":"K Goodyear","year":"2022","unstructured":"Goodyear K, Ahluwalia J, Chavanne D. The impact of race, gender, and heroin use on opioid addiction stigma. J Subst Abuse Treat. 2022;143:108872.","journal-title":"J Subst Abuse Treat"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-026-00665-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00665-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00665-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:44:00Z","timestamp":1781646240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-026-00665-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["665"],"URL":"https:\/\/doi.org\/10.1186\/s13722-026-00665-3","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Albert Einstein College of Medicine Institutional Review Board approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ADF receives royalties for an online chapter on primary care for patients with opioid use disorder from Wolters Kluwer. Other authors report no financial conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}